Pluvicto.
After we’ve been waiting almost a year, the FDA has finally approved Lu-177-PSMA for the treatment of metastatic prostate cancer after treatment with an androgen receptor pathway inhibitor and taxane. | FDA 2022
Search This Blog
With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
- Get link
- Other Apps
Comments
Post a Comment